Clindamycin Phosphate Lotion 1% — Competitive Intelligence Brief

Clindamycin Phosphate Lotion 1% (Clindamycin Phosphate Lotion 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Dermatology.

phase 3 Lincosamide antibiotic Bacterial 50S ribosomal subunit Dermatology Small molecule

Target snapshot

Clindamycin Phosphate Lotion 1% (Clindamycin Phosphate Lotion 1%) — Balmoral Medical company. Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clindamycin Phosphate Lotion 1% TARGET	Clindamycin Phosphate Lotion 1%	Balmoral Medical company	phase 3	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Oral Product	Azithromycin Oral Product	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1 gram IV	Azithromycin 1 gram IV	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin or placebo tablets	Azithromycin or placebo tablets	Rigshospitalet, Denmark	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

1. GlaxoSmithKline · 2 drugs in this class
2. Balmoral Medical company · 1 drug in this class
3. Generic (originally Upjohn/Pfizer) · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Janssen-Cilag, S.A. · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
8. Stiefel, a GSK Company · 1 drug in this class
9. Actavis Inc. · 1 drug in this class
10. University of Toronto · 1 drug in this class